TG Therapeutics, Inc. — Earnings Quality Grade F
TGTX · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO surged by 38 days (143 → 181)
AR outpaced revenue for 2 consecutive years
Revenue 87.3%, CFFO 38.9%. Cash follows revenue
Expense Quality
Inventory 13.7% vs COGS 161.7%. Normal
CapEx growth 375.6% is >2x revenue growth 87.3%
SG&A/Gross Profit = 45.0%. Normal
Gross margin 83.7%, change -4.6pp. Stable
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
FCF < 50% of Net Income for 3 years
Accruals ratio = 44.4%. Exceeds 10%
Cash $0.1B covers 56% of debt $0.3B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = 1.9x. Healthy
Other assets 0.4% vs revenue 87.3%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 2/3 years
No goodwill
Manipulation Score
M-Score = 22.77 (> -1.78). LIKELY MANIPULATOR
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25